[Double-blind study of the efficacy of an antiserotoninergic drug, pizotifen, in Duchenne's muscular dystrophy].

Abstract

In 40 patients presenting with Duchenne muscular dystrophy, a double blind therapeutic trial of 18 months was undertaken in order to appreciate the efficacy of pizotifen, an anti-serotoninergic drug. Quarterly evaluations were performed. Each of them included muscular testing on 31 pairs of muscles, timed tests, dynamometric study of the thumb-forefinger grip, functional testing, respiratory function tests, muscular enzyme determinations, parents' subjective estimation and search for side-effects. With respect to the evolution of Duchenne muscular dystrophy, this study did not show significant differences between pizotifen at a dose of 1.5 mg/day and placebo, except for a parents' preference for the drug.

• Authors: D Steru, J P Paclet, G Barthelet, G Gailliard, A Piton, E Monchartre, R Roche, J Galli, S Lancrenon, J Fermanian
• Journal: Archives francaises de pediatrie (Arch Fr Pediatr) 1987 Jun-Jul Vol. 44 Issue 6 Pg. 461-5 ISSN: 0003-9764 [Print] France
• Vernacular Title: Etude en double aveugle de l'efficacité d'un antisérotoninergique, le pizotifène, dans la myopathie de Duchenne de Boulogne.
• PMID: 3619586 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Thiophenes
• Pizotyline

Topics

• Child
• Child, Preschool
• Double-Blind Method
• Humans
• Male
• Muscle Contraction (drug effects)
• Muscular Dystrophies (drug therapy, genetics)
• Pizotyline (pharmacology, therapeutic use)
• Respiratory Function Tests
• Thiophenes (therapeutic use)